Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Primary Myelofibrosis"" wg kryterium: Temat


Tytuł:
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Autorzy:
Horvat NP; University of South Florida Health Morsani College of Medicine, 560 Channelside Dr., Tampa, FL, 33602, USA.
Abdallah EF; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Xie Z; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Al Ali N; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Yun S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Walker A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Sallman D; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Chan O; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Lancet J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Komrokji R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA.
Kuykendall AT; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 117-123. Date of Electronic Publication: 2023 Nov 30.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/therapy
Primary Myelofibrosis*/genetics
Hematopoietic Stem Cell Transplantation*/adverse effects
Young Adult ; Humans ; Female ; Aged ; Male ; Retrospective Studies ; Prognosis ; Comorbidity ; Mutation
Czasopismo naukowe
Tytuł:
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Autorzy:
Shide K; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan.
Takenaka K; Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Kitanaka A; Department of Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan.
Numata A; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Kameda T; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan.
Yamauchi T; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Inagaki A; Department of Hematology and Oncology, Nagoya City West Medical Center, Nagoya, Japan.
Mizuno S; Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Takami A; Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Ito S; Department of Hematology, Hakodate City Hospital, Hakodate, Japan.
Hagihara M; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
Usuki K; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
Maekawa T; Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Sunami K; Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Ueda Y; Department of Hematology/Oncology, Kurashiki Central Hospital, Okayama, Japan.
Tsutsui M; Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Ando M; Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Komatsu N; Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Ozawa K; Division of Hematology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Kurokawa M; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Arai S; Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Mitani K; Department of Hematology and Oncology, Dokkyo Medical University, Mibu, Tochigi, Japan.
Akashi K; Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Shimoda K; Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, 5200 Kihara Kiyotake, Miyazaki, 889-1692, Japan. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Jan; Vol. 103 (1), pp. 97-103. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Journal Article
MeSH Terms:
Polycythemia Vera*/complications
Polycythemia Vera*/diagnosis
Polycythemia Vera*/therapy
Thrombocythemia, Essential*/complications
Thrombocythemia, Essential*/diagnosis
Thrombocythemia, Essential*/drug therapy
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/etiology
Primary Myelofibrosis*/drug therapy
Humans ; Aged ; Prospective Studies
Czasopismo naukowe
Tytuł:
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation.
Autorzy:
Zhu P; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Lai X; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Liu L; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Shi J; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Yu J; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Zhao Y; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Yang L; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Yang T; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Zheng W; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Sun J; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Wu W; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Zhao Y; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Cai Z; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China.; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China.; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China.
Huang H; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China. .; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China. .; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China. .
Luo Y; Bone Marrow Transplantation Center of The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 311121, China. .; Institute of Hematology, Zhejiang University, Hangzhou, 311121, China. .; Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, 311121, China. .
Pokaż więcej
Źródło:
Journal of translational medicine [J Transl Med] 2024 Mar 13; Vol. 22 (1), pp. 275. Date of Electronic Publication: 2024 Mar 13.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/complications
Primary Myelofibrosis*/therapy
Hematopoietic Stem Cell Transplantation*
Myelodysplastic Syndromes*/therapy
Humans ; Retrospective Studies ; Transplantation, Homologous
Czasopismo naukowe
Tytuł:
Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib.
Autorzy:
Mesa R; Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC. .
Verstovsek S; The University of Texas MD Anderson Cancer Center, Houston, TX.
Platzbecker U; Leipzig University Hospital, Leipzig.
Gupta V; Princess Margaret Cancer Centre, Toronto, Ontario.
Lavie D; Hadassah-Hebrew University Medical Center, Jerusalem.
Giraldo P; Miguel Servet University Hospital and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza.
Recher C; Institut Universitaire du Cancer de Toulouse, Université de Toulouse III, Toulouse.
Kiladjian JJ; Université Paris Cité, AP-HP, Ho_pital Saint-Louis, Centre d'Investigations Cliniques, INSERM, CIC1427, Paris.
Oh ST; Washington University School of Medicine, St. Louis, MO.
Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Devos T; Department of Hematology, University Hospitals Leuven and Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.
Passamonti F; University of Insubria, Varese.
Vannucchi AM; University of Florence and AOU Careggi, Florence.
Egyed M; Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary.
Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Pluta A; Department of Hematological Oncology, Oncology Specialist Hospital, Brzozow, Poland.
Nilsson L; Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Shimoda K; University of Miyazaki, Miyazaki, Japan.
McLornan D; Guy's and St Thomas' NHS Foundation Trust, London.
Kawashima J; Sierra Oncology, Inc., San Mateo, CA.
Klencke B; Sierra Oncology, Inc., San Mateo, CA.
Huang M; Sierra Oncology, Inc., San Mateo, CA.
Strouse B; Sierra Oncology, Inc., San Mateo, CA.
Harrison C; Guy's and St Thomas' NHS Foundation Trust, London.
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Feb 01; Vol. 109 (2), pp. 676-681. Date of Electronic Publication: 2024 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/chemically induced
Benzamides*
Pyrazoles*
Humans ; Pyrimidines/adverse effects ; Nitriles ; Janus Kinase 2/genetics
Czasopismo naukowe
Tytuł:
Safe utilization of ruxolitinib in simultaneous primary myelofibrosis and warm autoimmune hemolytic anemia.
Autorzy:
Pope V; Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Hsia CC; Department of Medicine, Division of Hematology,, London Health Sciences Centre, Room E6-219A, Victoria Hospital, 800 Commissioners Road East, London, Ontario, Canada. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Feb; Vol. 103 (2), pp. 677-679. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Letter
MeSH Terms:
Primary Myelofibrosis*/complications
Primary Myelofibrosis*/drug therapy
Anemia, Hemolytic, Autoimmune*/drug therapy
Pyrazoles*
Humans ; Nitriles ; Pyrimidines
Opinia redakcyjna
Tytuł:
Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes.
Autorzy:
Mascarenhas J; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: .
Harrison C; Guy's and St Thomas' NHS Foundation Trust, London, UK.
Schuler TA; Cardinal Health, Dublin, OH.
Liassou D; Cardinal Health, Dublin, OH.
Garretson M; Cardinal Health, Dublin, OH.
Miller TA; Cardinal Health, Dublin, OH.
Mahadevan S; Bristol Myers Squibb, Princeton, NJ.
McBride A; Bristol Myers Squibb, Princeton, NJ.
Tang D; Bristol Myers Squibb, Princeton, NJ.
DeGutis IS; Bristol Myers Squibb, Princeton, NJ.
Abraham P; Bristol Myers Squibb, Princeton, NJ.
Kish J; Cardinal Health, Dublin, OH.
Feinberg BA; Cardinal Health, Dublin, OH.
Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Feb; Vol. 24 (2), pp. 122-132. Date of Electronic Publication: 2023 Sep 29.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/drug therapy
Nitriles*
Pyrazoles*
Pyrimidines*
Adult ; Humans ; Male ; Middle Aged ; Aged ; Aged, 80 and over ; Female ; Retrospective Studies ; Protein Kinase Inhibitors ; Pyrrolidines/therapeutic use ; Sulfonamides/therapeutic use
Czasopismo naukowe
Tytuł:
Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosis.
Autorzy:
Smallbone P; Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia; PathWest, Fiona Stanley Hospital, Perth, WA, Australia. Electronic address: .
Louw A; PathWest, Fiona Stanley Hospital, Perth, WA, Australia.
Purtill D; Department of Haematology, Fiona Stanley Hospital, Perth, WA, Australia; PathWest, Fiona Stanley Hospital, Perth, WA, Australia.
Pokaż więcej
Źródło:
Pathology [Pathology] 2024 Feb; Vol. 56 (1), pp. 24-32. Date of Electronic Publication: 2023 Nov 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/genetics
Primary Myelofibrosis*/therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*
Humans ; Transplantation, Homologous/adverse effects ; Neoplasm Recurrence, Local ; Recurrence ; Neoplasm, Residual/diagnosis
Czasopismo naukowe
Tytuł:
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Autorzy:
McLornan DP; Department of Haematology, University College London Hospitals, London, UK.
Godfrey AL; Haematopathology and Oncology Diagnostics Service, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Green A; Department of Histopathology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Frewin R; Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Arami S; Department of Haematology, London Northwest Healthcare University NHS Trust, London, UK.
Brady J; Department of Clinical Oncology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Butt NM; Department of Haematology, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
Cargo C; Department of Haematology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
Ewing J; Department of Haematology, University Hospitals Birmingham Trust, Birmingham, UK.
Francis S; Department of Haematology, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
Garg M; Department of Haematology, University Hospitals Leicester NHS Trust, Leicester, UK.
Harrison C; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Innes A; Department of Haematology, Imperial College, London, UK.
Khan A; Department of Haematology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
Knapper S; Department of Haematology, Cardiff University, Cardiff, UK.
Lambert J; Department of Haematology, University College London Hospitals, London, UK.
Mead A; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Haematology, Churchill Hospital, Oxford University NHS Trust, Oxford, UK.
McGregor A; Department of Haematology, Freeman Hospital, Newcastle upon Tyne, UK.
Neelakantan P; Department of Haematology, Royal Berkshire NHS Foundation Trust, Berkshire, UK.
Psaila B; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Haematology, Churchill Hospital, Oxford University NHS Trust, Oxford, UK.
Somervaille TCP; Cancer Research UK Manchester Institute and The Christie NHS Foundation Trust, Manchester, UK.
Woodley C; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Nangalia J; Wellcome Sanger Institute, University of Cambridge, Cambridge, UK.
Cross NCP; Faculty of Medicine, University of Southampton, Southampton, UK.
McMullin MF; Centre for Medical Education, Queen's University, Belfast, UK.
Pokaż więcej
Corporate Authors:
BSH Committee
Źródło:
British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 127-135. Date of Electronic Publication: 2023 Nov 06.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/therapy
Hematology*
Humans ; Prognosis
Czasopismo naukowe
Tytuł:
The management of myelofibrosis: A British Society for Haematology Guideline.
Autorzy:
McLornan DP; Department of Haematology, University College London Hospitals, London, UK.
Psaila B; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Haematology, Churchill Hospital, Oxford University NHS Trust, Oxford, UK.
Ewing J; Department of Haematology, University Hospitals Birmingham Trust, London, UK.
Innes A; Department of Haematology, Imperial College, London, UK.
Arami S; Department of Haematology, London Northwest Healthcare University NHS Trust, London, UK.
Brady J; Department of Clinical Oncology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Butt NM; Department of Haematology, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK.
Cargo C; Department of Haematology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
Cross NCP; Faculty of Medicine, University of Southampton, Southampton, UK.
Francis S; Department of Haematology, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
Frewin R; Department of Haematology, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK.
Garg M; Department of Haematology, University Hospitals Leicester NHS Trust, Leicester, UK.
Godfrey AL; Haematopathology & Oncology Diagnostics Service, Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Green A; Department of Histopathology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Khan A; Department of Haematology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds, UK.
Knapper S; Department of Haematology, Cardiff University, Cardiff, UK.
Lambert J; Department of Haematology, University College London Hospitals, London, UK.
McGregor A; Department of Haematology, Freeman Hospital, Newcastle, UK.
McMullin MF; Centre for Medical Education, Queen's University, Belfast, UK.
Nangalia J; Wellcome Sanger Institute, University of Cambridge, Cambridge, UK.
Neelakantan P; Department of Haematology, Royal Berkshire NHS Foundation Trust, London, UK.
Woodley C; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Mead A; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.; Department of Haematology, Churchill Hospital, Oxford University NHS Trust, Oxford, UK.
Somervaille TCP; Cancer Research UK Manchester Institute & The Christie NHS Foundation Trust, Manchester, UK.
Harrison CN; Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Pokaż więcej
Corporate Authors:
BSH Committee
Źródło:
British journal of haematology [Br J Haematol] 2024 Jan; Vol. 204 (1), pp. 136-150. Date of Electronic Publication: 2023 Dec 01.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/therapy
Hematology*
Hematopoietic Stem Cell Transplantation*
Humans
Czasopismo naukowe
Tytuł:
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Autorzy:
Loscocco GG; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.; Doctorate School GenOMec, University of Siena, Siena, Italy.
Rotunno G; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Mannelli F; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Coltro G; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Gesullo F; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Pancani F; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Signori L; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Maccari C; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Esposito M; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Paoli C; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Vannucchi AM; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Guglielmelli P; Department of Experimental and Clinical Medicine, CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Florence, Italy.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Jan; Vol. 99 (1), pp. 68-78. Date of Electronic Publication: 2023 Oct 17.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factor Alpha 2 Subunit*/genetics
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/genetics
Male ; Humans ; Middle Aged ; Female ; Prognosis ; Proto-Oncogene Proteins p21(ras)/genetics ; Mutation ; Tumor Suppressor Protein p53/genetics ; Membrane Proteins/genetics ; GTP Phosphohydrolases/genetics
Czasopismo naukowe
Tytuł:
Thrombopoietin mimetic-induced bone marrow fibrosis.
Autorzy:
Harper K; Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Bagot C; Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK.
Leach M; Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Bain BJ; Centre for Haematology, Department of Immunology and Inflammation, St. Mary's Hospital Campus of Imperial College London School of Medicine, London, UK.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Jan; Vol. 99 (1), pp. 135-136. Date of Electronic Publication: 2023 Nov 11.
Typ publikacji:
Case Reports
MeSH Terms:
Primary Myelofibrosis*/drug therapy
Primary Myelofibrosis*/chemically induced
Humans ; Thrombopoietin/adverse effects ; Megakaryocytes ; Bone Marrow Cells
Raport
Tytuł:
Impact of CALR and JAK2 V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.
Autorzy:
Narlı Özdemir Z; İzmir City Hospital, Clinic of Hematology, İzmir, Türkiye.
İpek Y; Kartal Dr. Lüfti Kırdar City Hospital, Clinic of Hematology, İstanbul, Türkiye.
Patır P; Antalya Training and Research Hospital, Clinic of Hematology, Antalya, Türkiye.
Ermiş G; Karadeniz Technical University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Trabzon, Türkiye.
Çiftçiler R; Selçuk University Faculty of Medicine, Department of Hematology, Konya, Türkiye.
Özmen D; İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye.
Baysal M; Ali Osman Sönmez Oncology Hospital, Clinic of Hematology, Bursa, Türkiye.
Gürsoy V; Bursa City Hospital, Clinic of Orthopedics and Traumatology, Bursa, Türkiye.
Yıldızhan E; Kayseri City Hospital, Clinic of Hematology, Kayseri, Türkiye.
Güven S; Mehmet Akif Ersoy State Hospital, Clinic of Hematology, Çanakkale, Türkiye.
Ercan T; Haydarpaşa Numune Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Elibol T; Medeniyet University Göztepe Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Mersin S; Muğla Sıtkı Koçman University Training and Research Hospital, Clinic of Hematology, Muğla, Türkiye.
Genç E; Tekirdağ Dr. İsmail Fehmi Cumalıoğlu City Hospital, Clinic of Hematology, Tekirdağ, Türkiye.
Davulcu EA; University of Health Sciences Türkiye, İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Clinic of Hematology, İstanbul, Türkiye.
Karakuş V; Antalya Training and Research Hospital, Clinic of Hematology, Antalya, Türkiye.
Erkut N; Karadeniz Technical University Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Trabzon, Türkiye.
Güneş G; University of Health Sciences Türkiye, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Hematology, Ankara, Türkiye.
Diz Küçükkaya R; İstanbul University Faculty of Science, Department of Molecular Biology and Genetics, İstanbul, Türkiye.
Eşkazan AE; İstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Internal Medicine, Division of Hematology, İstanbul, Türkiye.
Pokaż więcej
Źródło:
Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 26-36.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Primary Myelofibrosis*
Thrombocythemia, Essential*/drug therapy
Thrombocythemia, Essential*/genetics
Thrombosis*/etiology
Thrombosis*/genetics
Humans ; Calreticulin/genetics ; Disease Progression ; Hemoglobins ; Mutation ; Retrospective Studies ; Turkey/epidemiology
Czasopismo naukowe
Tytuł:
Extreme thrombocytosis with an aggressive evolution harboring a novel variant of calreticulin (CALR) in exon 3.
Autorzy:
Bonnet S; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.
Carillo S; Département d'Hématologie biologique, Laboratoire de Cytologie Clinique et Cytogénétique, CHRU Nîmes, Nîmes, France.
Legrand B; IBMM, Univ Montpellier, CNRS, ENSCM, Montpellier, France.
Burroni B; Centre de Recherche des Cordeliers, Sorbonne Université, Inserm, UMRS 1138, Université de Paris Cité, Paris, France.; Department of Pathology Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Cochin, Paris, France.
Lavabre-Bertrand T; Département d'Hématologie biologique, Laboratoire de Cytologie Clinique et Cytogénétique, CHRU Nîmes, Nîmes, France.
Requirand G; Institut de Génétique Humaine, UMR 9002 CNRS-UM, Montpellier, France.; Pôle de biologie, Centre Hospitalier Universitaire, Montpellier, France.
Robert N; Institut de Génétique Humaine, UMR 9002 CNRS-UM, Montpellier, France.; Pôle de biologie, Centre Hospitalier Universitaire, Montpellier, France.
Fornero L; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.
Al Mansoori A; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.
Moreaux J; Institut de Génétique Humaine, UMR 9002 CNRS-UM, Montpellier, France.; Pôle de biologie, Centre Hospitalier Universitaire, Montpellier, France.
Cartron G; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.
Gabellier L; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.; Institut de Génétique Moléculaire de Montpellier, CNRS-UMR5535, Montpellier, France.
Herbaux C; Département d'Hématologie Clinique, CHRU Montpellier, Montpellier, France.; Institut de Génétique Humaine, UMR 9002 CNRS-UM, Montpellier, France.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 475-478. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Case Reports
MeSH Terms:
Thrombocytosis*/diagnosis
Primary Myelofibrosis*/genetics
Myelodysplastic-Myeloproliferative Diseases*/complications
Myeloproliferative Disorders*/genetics
Humans ; Calreticulin/genetics ; Calreticulin/metabolism ; Mutation ; Exons ; Janus Kinase 2/genetics
Raport
Tytuł:
Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis.
Autorzy:
Abbonante V; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Karkempetzaki AI; Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.; School of Medicine, University of Crete, Heraklion, Greece.
Leon C; INSERM, EFS Grand Est, BPPS UMR-S 1255, Université de Strasbourg, Strasbourg, France.
Krishnan A; Institute of Immunology, Stanford University School of Medicine, Palo Alto, California, United States.
Huang N; Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Di Buduo CA; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Cattaneo D; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Ward CM; Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Matsuura S; Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Guinard I; INSERM, EFS Grand Est, BPPS UMR-S 1255, Université de Strasbourg, Strasbourg, France.
Weber J; INSERM, EFS Grand Est, BPPS UMR-S 1255, Université de Strasbourg, Strasbourg, France.
De Acutis A; Interdepartmental Research Center 'E. Piaggio', University of Pisa, Pisa, Italy.
Vozzi G; Interdepartmental Research Center 'E. Piaggio', University of Pisa, Pisa, Italy.
Iurlo A; Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Ravid K; Department of Medicine and Whitaker Cardiovascular Institute, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Balduini A; Department of Molecular Medicine, University of Pavia, Pavia, Italy.; Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Mar; Vol. 99 (3), pp. 336-349. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article
MeSH Terms:
Primary Myelofibrosis*/genetics
Thrombocythemia, Essential*/metabolism
Humans ; Animals ; Mice ; Megakaryocytes/metabolism ; Bone Marrow ; Thrombopoiesis/genetics ; Blood Platelets/metabolism ; Ion Channels/genetics ; Ion Channels/metabolism
Czasopismo naukowe
Tytuł:
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
Autorzy:
Larsen MK; Department of Hematology, Zealand University Hospital, Roskilde, Denmark. .; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. .
Skov V; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Kjær L; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Eickhardt-Dalbøge CS; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Knudsen TA; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Kristiansen MH; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
Sørensen AL; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.
Wienecke T; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Neurology, Zealand University Hospital, Roskilde, Denmark.
Andersen M; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Ottesen JT; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Gudmand-Høyer J; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Snyder JA; Department of Science and Environment, Roskilde University, Roskilde, Denmark.
Andersen MP; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.
Torp-Pedersen C; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.
Poulsen HE; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, Copenhagen University Hospital, Nordsjællands Hospital, Hillerød, Denmark.; Department of Endocrinology, Copenhagen University Hospital, Bispebjerg Frederiksberg Hospital, Copenhagen, Denmark.
Stiehl T; Department of Science and Environment, Roskilde University, Roskilde, Denmark.; Institute for Computational Biomedicine - Disease Modelling, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Hasselbalch HC; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Ellervik C; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Biochemistry, Zealand University Hospital, Koege, Denmark.; Department of Laboratory Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Feb 09; Vol. 14 (1), pp. 28. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myeloproliferative Disorders*/epidemiology
Polycythemia Vera*
Primary Myelofibrosis*/epidemiology
Thrombocythemia, Essential*/epidemiology
Humans ; Longitudinal Studies ; Neutrophils ; Lymphocytes ; Denmark/epidemiology
Czasopismo naukowe
Tytuł:
Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms.
Autorzy:
Holl K; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Chatain N; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.
Krapp S; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Baumeister J; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.
Maié T; Institute for Computational Genomics, Joint Research Center for Computational Biomedicine, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Schmitz S; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Scheufen A; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Brock N; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.
Koschmieder S; Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.; Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen, Germany.
Moreno-Andrés D; Institute of Biochemistry and Molecular Cell Biology, Faculty of Medicine, RWTH Aachen University, Aachen, Germany. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2024 Feb 02; Vol. 14 (1), pp. 2810. Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:
Journal Article
MeSH Terms:
Myeloproliferative Disorders*/genetics
Polycythemia Vera*/genetics
Primary Myelofibrosis*/genetics
Animals ; Humans ; Mice ; Calreticulin/genetics ; Calreticulin/metabolism ; Janus Kinase 2/genetics ; Janus Kinase 2/metabolism ; Mutation ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
Autorzy:
Tefferi A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Pardanani A; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Gangat N; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2024 Feb; Vol. 99 (2), pp. 300-308. Date of Electronic Publication: 2024 Jan 02.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Primary Myelofibrosis*/diagnosis
Anemia*/complications
Benzamides*
Bridged-Ring Compounds*
Pyrazoles*
Pyrimidines*
Humans ; Splenomegaly/drug therapy ; Splenomegaly/etiology ; Nitriles/therapeutic use ; Janus Kinase 2 ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Early liver complications after allogeneic haematopoietic stem cell transplantation in patients with myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of the EBMT.
Autorzy:
Robin M; Hôpital Saint Louis, APHP, Université de Paris Cité, Paris, France.
Gras L; EBMT Statistical Unit, Leiden, The Netherlands.
Koster L; EBMT Data Office, Leiden, The Netherlands.
Gagelmann N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
van Gorkom G; Department of Internal Medicine, Hematology and Oncology, University Hospital Maastricht, Maastricht, The Netherlands.
Ederr M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Itälä-Remes M; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Zuckerman T; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
Beguin Y; Department of Hematology, CHU Liege, University of Liege, Liege, Belgium.
Schaap N; Radboud University Medical Centre, Nijmegen, The Netherlands.
Drozd-Sokolowska J; Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Raj K; Department of Haematology, University College London Hospitals NHS Trust, London, UK.
Hayden PJ; Trinity College Dublin, St. James's Hospital, Dublin, Ireland.
de Wreede LC; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands.
Battipaglia G; Hematology Department, Federico II University of Naples, Naples, Italy.
Polverelli N; Unit of Bone Marrow Transplantation - Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Czerw T; Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Hernandez Boluda JC; Department of Hematology, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain.
Kröger N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Yakoub-Agha I; Centre Hospitalier Universitaire de Lille LIRIC, INSERM U1286, Université de Lille, Lille, France.
McLornan DP; Department of Haematology, University College London Hospitals NHS Trust, London, UK.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2024 Feb; Vol. 204 (2), pp. 715-718. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Letter
MeSH Terms:
Primary Myelofibrosis*
Hematopoietic Stem Cell Transplantation*
Neoplasms*
Graft vs Host Disease*
Humans ; Transplantation, Homologous ; Liver ; Transplantation Conditioning ; Retrospective Studies
Opinia redakcyjna
Tytuł:
Overt primary myelofibrosis with coexistence of JAK2V617F and MPLW515R driver mutations.
Autorzy:
Wang Y; Physical Examination Center, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Fan D; Department of Pathology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Zhang X; Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2024 Feb; Vol. 46 (1), pp. 180-182. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Letter
MeSH Terms:
Primary Myelofibrosis*/genetics
Myeloproliferative Disorders*/genetics
Humans ; Mutation ; Janus Kinase 2/genetics
Opinia redakcyjna
Tytuł:
Type 1 CALR mutation allele frequency correlates with CD34/CXCR4 expression in myelofibrosis-type megakaryocyte dysplasia: A mechanism of disease progression?
Autorzy:
Barosi G; Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy. .
Campanelli R; Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy.
Catarsi P; Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy.
Abbà C; General Medicine 2, Center for Sistemic Amyloidosis and High Complexity Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Carolei A; Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy.
Massa M; General Medicine 2, Center for Sistemic Amyloidosis and High Complexity Diseases, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo Foundation, Pavia, Italy.
Gale RP; Centre for Haematology Research, Imperial College London, London, UK.
Rosti V; Center for the Study of Myelofibrosis, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S. Matteo Foundation, Pavia, Italy.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2024 Jan 23; Vol. 14 (1), pp. 18. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Primary Myelofibrosis*/genetics
Humans ; Megakaryocytes ; Disease Progression ; Mutation ; Receptors, CXCR4/genetics
Raport

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies